The Bocx, in the real world, marketing partners and the financing to market a product do not happen as a result of putting out a press release. However, your thought process on press releases makes the current $0.07 cent BioCurex share price more understandable. kag
Your argument about recaf after a positive mammogram will avoid unnecessary biopsies and confirm a malignancy if presented to the FDA would likely get us fast tracked. It seems pretty compelling to me. A no brainer when you combine much greater odds that the biopsy is necessary with the cost savings. If you haven't presented those facts to Dr Moro please make sure he has those numbers handy. At least with the education (and the drubbing) you are giving Goldsseker I feel even better about the future of recaf and Biocurex. Awesome job! Good stuff.
News 
Market Data 
Discover 
